27,980 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Bought by Natixis Advisors LLC

Natixis Advisors LLC bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 27,980 shares of the company’s stock, valued at approximately $1,621,000. Natixis Advisors LLC owned about 0.06% of Astrana Health as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. SteelPeak Wealth LLC acquired a new stake in shares of Astrana Health in the third quarter valued at about $39,398,000. NorthCrest Asset Manangement LLC acquired a new stake in Astrana Health during the 3rd quarter valued at approximately $26,704,000. Principal Financial Group Inc. acquired a new position in shares of Astrana Health in the 3rd quarter worth approximately $13,383,000. F M Investments LLC acquired a new position in shares of Astrana Health in the 3rd quarter worth approximately $11,738,000. Finally, Diamond Hill Capital Management Inc. bought a new stake in shares of Astrana Health in the 3rd quarter valued at $8,245,000. 52.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on ASTH shares. Robert W. Baird boosted their target price on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Truist Financial increased their price target on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Astrana Health currently has a consensus rating of “Buy” and a consensus price target of $65.17.

Astrana Health Stock Performance

ASTH opened at $42.40 on Tuesday. Astrana Health, Inc. has a 1-year low of $32.32 and a 1-year high of $63.20. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 1.95 and a beta of 1.24. The company’s fifty day moving average price is $54.17 and its two-hundred day moving average price is $47.94. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. During the same quarter last year, the firm earned $0.47 EPS. On average, analysts expect that Astrana Health, Inc. will post 1.17 EPS for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.